



CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

Name Nicholas M. N.

Date 11/1/04

98204.00007

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)	
)	
Robert H. Zimmer)	Examiner:
)	
Serial No.: 09/844,426)	Group Art Unit: 1617
)	
Filed: August 7, 2000)	Confirmation No. 3123

For: PROCESS TO IMPROVE OR PERMIT THE ORAL ABSORPTION OF
POLYPEPTIDE DRUG SUBSTANCES AND OTHER POORLY ORALLY
ABSORBED DRUGS WHILE MAINTAINING THEIR
PHARMACOLOGICAL EFFECTS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

In accordance with 37 C.F.R. § 1.56, the documents listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with examination of the above-identified patent application.

This Information Disclosure Statement is being filed after the mailing date of a Final Office Action in connection with the present application. (See 37 CFR § 1.98(d)). Applicant notes the requirements of Section 1.98(d) and acknowledges the absence of a statement pursuant to 37 CFR § 1.98(e) in connection with the present submission.

Accordingly, applicant hereby requests that the documents submitted herewith be placed of record in the file for the present application pursuant to 37 CFR § 1.98(i). In the event the Examiner elects to enter the present Information Disclosure Statement for substantive consideration, applicant authorizes the Patent Office to charge any applicable fees associated with the submission of this Information Disclosure Statement to Deposit Account No. 501402. **A duplicate copy of this sheet is enclosed.**

The filing of this Information Disclosure Statement shall not be construed to be a representation that a search has been conducted, nor shall it be construed as an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

In the event the present submission is entered by the Examiner, it is respectfully requested that the Examiner return a copy of the attached form PTO-1449 with initials or other appropriate marks indicating consideration of the cited materials.

Respectfully submitted,

Date: November 1, 2004



Basam E. Nabulsi
Reg. No. 31,645
Attorney for Applicants
McCarter & English, LLP
Four Stamford Plaza
107 Elm Street
Stamford, CT 06902
(203) 965-0601

HARTFORD: 625031.01

Form PTO-1449
(modified 2/91)U.S. DEPT OF COMMERCE
Patent and Trademark Office

Attorney Docket Number:

Serial No.:

98204.00007

10/844,426

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Applicants:

Robert H. Zimmer

Filing date:

8/7/2000

Group Art Unit:

1617

U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate
	4,239,754	12/16/1980	Sache et al.			
	4,339,534	7/13/1982	Johansen et al.			
	4,925,673	5/15/1990	Steiner et al.			
	5,212,158	5/18/1993	Vandai			
	6,136,952	10/24/2000	Li et al.			
	2002/0090603	7/11/2002	Lipton et al.			

FOREIGN PATENT DOCUMENTS

	Document number	Date	Country	Class	Sub class	Translation Yes No
WO	98/11126	3/19/1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Fukushima, K., Hypoglycemic Effect and Enhanced Gastrointestinal Absorption of Insulin Using New Cinnamoyl-phenylalanine Derivatives, Hokkaido Journal of Medical Science, Vol. 71, No. 6, 1996, pp. 727-743.
	Vergnolle, N., et al., Proteinase-Activated Receptor 2 (PAR ₂)-Activating Peptides: Identification of A Receptor Distinct From PAR ₂ That Regulates Intestinal, Transport, Proceedings of the National Academy of Sciences of USA, National Academy of Science, Vol. 95, June 1998 (1998-06), pp. 7766-7771.
	Langguth, P., et al., The Challenge of Proteolytic Enzymes in Intestinal Peptide Delivery, Journal of Controlled Release, Elsevier Science Publishers B.V. Amsterdam, NL, Vol. 46, No. 1, May 1997, pp. 39-57.
	Egleton, R.D., et al., Improved Bioavailability to the Brain of Glycosylated Met-Enkephalin Analogs, Brain Research, Vol. 881, NO. 1, 2000, pp. 37-46.
	Pauletti, G.M., et al., Improvement of Oral Peptide Bioavailability: Peptidomimetics and Prodrug Strategies, Advanced Drug Delivery Review, Vol. 27, No. 2-3, 1997, pp. 235-256.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

Form PTO-1449
(modified 2/91)U.S. DEPT OF COMMERCE
Patent and Trademark Office

Attorney Docket Number:

Serial No.:

98204.00007

10/844,426

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Applicants:

Robert H. Zimmer

Filing date:

8/7/2000

Group Art Unit:

1617

U.S. PATENT DOCUMENTS

Examiner Initial	Patent number	Date	Inventor	Class	Sub class	Filing date if appropriate

FOREIGN PATENT DOCUMENTS

Document number	Date	Country	Class	Sub class	Translation Yes No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Ahlers, et al., Enhanced Immunogenicity of HIV-1 Vaccine Construct By Modification of the Native Peptide Sequence, Proc. Natl. Acad. Sci. USA, Vol. 94, pp. 10856-10861, September 1997.
	Greenstein, et al., A Universal T Cell Epitope-Containing Peptide From Hepatitis B Surface Antigen Can Enhance Antibody Specific For HIV gp120, Journal of Immunology, Vol. 148, pp. 3970-3977, No. 12, June 1992.
	Belyakov, et al., The Importance of Local Mucosal HIV-Specific CD8 ⁺ Cytotoxic T Lymphocytes For Resistance to Mucosal Viral Transmission in Mice and Enhancement of Resistance by Local Administration of IL-12, The Journal of Clinical Investigation, Vol. 102(12); pp. 2072-2081, December 1998.
	Belyakov, et al., Mucosal Immunization With HIV-1 Peptide Vaccine Induces Mucosal and Systemic Cytotoxic T Lymphocytes and Protective Immunity In Mice Against Intrarectal Recombinant HIV_Vaccinia Challenge, Proc. Natl. Acad. Sci. USA, Vol. 95, pp. 1709-1714, February 1998.
	Patel, et al., Oral Administration of Insulin By Encapsulation Within Liposomes, North-Holland Publishing Company, Volume 62, No. 1, pp. 60-63, February 1976.
	Hashimoto, et al., ACTH Release in Pituitary Cell Cultures, Effect of Neurogenic Peptides and Neurotransmitter Substances Corticotropin Releasing Factor (CRF), Endocrinol. Japan, Vol. 26 (1), pp. 103-109, February 1979.

Examiner:

Date Considered:

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.